DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar, G. N.
Right arrow Articles by Dennisen, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, G. N.
Right arrow Articles by Dennisen, J. F.

0090-9556/97/2501-0110-0115$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 1

Identification of Cytochromes P450 Involved in the Human Liver Microsomal Metabolism of the Thromboxane A2 Inhibitor Seratrodast (ABT-001)

Gondi N. Kumar, Erik Dubberke, A. David Rodrigues, Ellen Roberts, and Jon F. Dennisen

Biotransformation Department, Abbott Laboratories

Seratrodast (ABT-001, AA-2414) undergoes cytochrome P450 (CYP)-dependent metabolism to a major (5-methylhydroxy seratrodast; 5-HOS) and a minor 4'-hydroxy seratrodast metabolite in human liver microsomes. The mean apparent Km and Vmax for the formation of 5-HOS were 15.5 µM and 589.0 pmol 5-HOS formed/mg protein/min, respectively. Chemical inhibition using isoform-selective CYP inhibitors, correlation of 5-HOS formation with several isoform-specific CYP activities in a panel of liver microsomes, metabolism by microsomes derived from CYP cDNA-expressed B-lymphoblastoid cells, and immunoinhibition by isoform-specific anti-CYP antibodies indicated that 5-HOS formation is catalyzed by CYP3A and CYP2C9/10, with a minor contribution from CYP2C8 and CYP2C19. At clinically relevant concentrations, seratrodast was found to inhibit tolbutamide methylhydroxylation (IC50 = 60 µM), (S)-mephenytoin 4'-hydroxylation (IC50 = 50 µM), and coumarin 7-hydroxylation (IC50 = 95 µM), indicating the potential for significant clinical interactions. The inducers of CYP3A and/or CYP2C9 (e.g. rifampicin and phenytoin) are likely to alter the disposition of seratrodast.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
A. Ghosal, S. K. Chowdhury, W. Tong, N. Hapangama, Y. Yuan, A.-D. Su, and S. Zbaida
IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR)
Drug Metab. Dispos., April 1, 2006; 34(4): 628 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M.-S. Baek, J.-Y. Kim, S.-W. Myung, Y. H. Yim, J.-H. Jeong, and D.-H. Kim
Metabolism of Dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) by Human Liver Microsomes: Characterization of Metabolic Pathways and of Cytochrome P450 Isoforms Involved
Drug Metab. Dispos., April 1, 2001; 29(4): 381 - 388.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Ludwig, J. Schmid, K. Beschke, and T. Ebner
Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5'-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 1 - 8.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.